COMMUNIQUÉ DE PRESSE
News
-
-
-
COMMUNIQUÉ DE PRESSE
Bio Usawa becomes partner for the commercialization of FYB201/ BioUcenta™ (ranibizumab) across Sub-Saharan Africa
Bio Usawa partners with Formycon AG for the commercialization of FYB201/BioUcenta™ (ranibizumab) in Sub-Saharan Africa, expanding access to ophthalmic treatment for diabetic complications -
-
-
-
COMMUNIQUÉ DE PRESSE
There is a Strong Business Case for Phase II Clinical Program for Treatment of MPox Infection Using NV-387, an Industry-Leading Broad-Spectrum Antiviral Drug Candidate
NanoViricides, Inc. announces advancing lead candidate NV-387 into Phase II clinical development for MPox. Protocol development and site addition underway in the DRC. Focus on antiviral drug against MPox/Smallpox -
-
COMMUNIQUÉ DE PRESSE
Market analysis by Kirchhoff and CMS: Every fourth company in the DAX160 voluntarily publishes preliminary figures
Market analysis by Kirchhoff Consult and CMS reveals that 1 in 4 DAX160 companies voluntarily release preliminary financial figures, posing legal risks and transparency challenges. Recommendations for communication and legal protection provided -
